Jakarta, June 11, 2020 - PT Kalbe Farma Tbk (Kalbe) took part in clinical trials on herbal medicines made from Indonesian biodiversity as herbal immunomodulatory products in the handling of COVID-19 patients that is coordinated by the Covid-19 Research Consortium/BRIN. The 2 products that will take part in the clinical trial are products based on Cordyceps militaris and a combination of extracted ingredients made from extracts of red ginger, gripeweed, Green chiretta, and Ngai camphor. The clinical trial is a collaboration of the Indonesian Institute of Sciences (LIPI), Kalbe, Gadjah Mada University (UGM), and the Association of Indonesian Traditional Medicine and Herbal Medicine Developers (PDPOTJI). 

Jakarta, May 27, 2020, PT Kalbe Farma Tbk (Kalbe) signed a memorandum of understanding with Genexine, Inc., a biological drug company from South Korea to develop a vaccine for the new corona virus or Covid-19 . Kalbe and Genexine has agreed to conduct GX-19 clinical trials in Indonesia, that is the development of DNA vaccines against new corona virus, to be carried out by the consortium of Genexine, Binex, the International Vaccine Institute (IVI), GenNBio, the Korea Advanced Institute of Science & Technology (KAIST), and Pohang University of Science & Technology (POSTECH). Covid-19 vaccine clinical trial is planned to be conducted in June 2020. 

Jakarta, 22 May 2020, PT Kalbe Farma Tbk (Kalbe) through the Kalbe Consumer Health Division donated hand sanitizers to several COVID-19 Referral Hospitals in Jabodetabek via the National Disaster Management Agency (BNPB). The presentation of the 5,000 bottles of hand sanitizer was symbolically carried out by Feni Herawati, Director of Consumer Health Division of PT Kalbe Farma Tbk to Colonel Cba Agung Maryono, Sub Commander of the Supplies and Donations Task Force of the Emergency COVID-19 Hospital of Wisma Atlet, Jakarta. 

Jakarta, May 18, 2020 – PT Kalbe Farma Tbk (“Kalbe” or “the Company”) will distribute cash dividend of Rp 937.5 Billion. The dividend distribution of Rp 20 per share or equivalent to a dividend payout ratio of around 37% of fiscal year 2019 net income, has been approved by the shareholders of the Company in the Annual General Meeting of Shareholders (“AGMS”) held on May 18, 2020 in Gedung Bintang Toedjoe, Pulomas, Jakarta. In compliance with the prevailing regulations, dividend payment will be made at the latest within 30 days after the announcement of AGMS where the Company will shortly announce the schedule and procedures.